News
BIOVF
25.00
NaN%
--
Weekly Report: what happened at BIOVF last week (0422-0426)?
Weekly Report · 6d ago
Swedish Orphan Biovitrum AB reports Q1 results
Seeking Alpha · 04/25 17:36
Weekly Report: what happened at BIOVF last week (0415-0419)?
Weekly Report · 04/22 12:17
Weekly Report: what happened at BIOVF last week (0408-0412)?
Weekly Report · 04/15 12:06
Weekly Report: what happened at BIOVF last week (0401-0405)?
Weekly Report · 04/08 12:13
Weekly Report: what happened at BIOVF last week (0325-0329)?
Weekly Report · 04/01 12:09
Weekly Report: what happened at BIOVF last week (0318-0322)?
Weekly Report · 03/25 12:13
Weekly Report: what happened at BIOVF last week (0311-0315)?
Weekly Report · 03/18 12:11
Weekly Report: what happened at BIOVF last week (0304-0308)?
Weekly Report · 03/11 12:06
Weekly Report: what happened at BIOVF last week (0226-0301)?
Weekly Report · 03/04 12:10
Weekly Report: what happened at BIOVF last week (0219-0223)?
Weekly Report · 02/26 12:29
Weekly Report: what happened at BIOVF last week (0212-0216)?
Weekly Report · 02/19 12:32
Weekly Report: what happened at BIOVF last week (0205-0209)?
Weekly Report · 02/12 12:17
Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK3.21, revenue of SEK6.84B
Seeking Alpha · 02/08 11:11
Weekly Report: what happened at BIOVF last week (0129-0202)?
Weekly Report · 02/05 12:30
All You Need to Know About Swedish Orphan Biovitrum (BIOVF) Rating Upgrade to Strong Buy
NASDAQ · 02/01 17:00
Weekly Report: what happened at BIOVF last week (0122-0126)?
Weekly Report · 01/29 12:12
Weekly Report: what happened at BIOVF last week (0115-0119)?
Weekly Report · 01/22 12:18
Weekly Report: what happened at BIOVF last week (0108-0112)?
Weekly Report · 01/15 12:12
First RSV shots, groundbreaking gene therapy among 2024 drugs to watch
First RSV vaccines, groundbreaking gene therapy among 2024 drugs to watch. Report highlights 13 recently launched or upcoming drugs with game-changing potential. Regeneron's eye disease therapy, high-dose Eylea leads the list. New technology platforms are expected to be used in drug development in 2024.
Seeking Alpha · 01/14 17:00
More
Webull provides a variety of real-time BIOVF stock news. You can receive the latest news about Swedish Orphan Biovitrum Ab through multiple platforms. This information may help you make smarter investment decisions.
About BIOVF
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.